One or more speakers from all partners will present the recents developments in the framework of the project
Speaker: Filippo Pisano
Speaker: Liset De La Prida
Speakers: Manuel Valiente and Mariam Al-Masmudi
Speaker: Chengjie Ding
Speaker: Liam Conlard
15:00 - 15:20 CNIO - Manuel Valiente
15:20 - 15:40 IIT - Ferruccio Pisanello, Cristian Ciracì
15:40 - 16:00 CNRS - Marianna Amato
16:00 - 16:20 CSIC - Liset M. De La Prida
CNIO: The Brain Metastasis Group (CNIO) has the goal of providing the known-how for applying clinically relevant questions to interrogate experimental and human-derived brain tumors. We are specifically interested in exploiting diagnostic and therapeutic opportunities within Nanobright to challenge the lethality of this unmet clinical need in oncology.
IIT: We will describe recent results and related issues concerning (i) the numerical estimation of the electromagneic field profile along tapered fibers, (ii) the spatial-sective activation of a subset of hotspots on flat-cleaved fibers
CNRS: We will present a technique to design and fabricate ultrahigh trasmission optical nanofibers characterized by a highly confined and intense evanescent field at the nanofiber surface. With this compact optical platform it is possibile to couple light with small structures deposited on the surface, in order to study the interaction between the guided electromagnetic modes and matter.
CSIC: Extracellular mapping of brain metastasis and TBI. We will discuss rhythmopathies accompanying brain metastasis and traumatic brain injury (TBI), and how they can be integrated with multifunctional neural implants for better delination of epileptogenic territories.
15:30 - 16:00 Webinar: Filippo Pisano
16:00 - 16:30 Progress report: Filippo Pisano
15:30 - 16:00 Webinar: Liset De La Prida
16:00 - 16:30 Progress report: Liset De La Prida
15:30 - 16:00 Webinar: Manuel Valiente "Why is Nanobright a unique opportunity for brain tumors"
16:00 - 16:30 Progress report: Mariam Al-Masmudi "Applying light to improve drug access to the brain and to classify different tumor entities"
ABSTRACT: Upon diagnosis of a brain tumor (primary or secondary) patients face a dismal prognosis. Very aggressive treatments including surgery are frequently applied with palliative rather than curative results since systemic therapies do not reach significant results in the majority of patients. Decreasing the aggressive management by limiting the need of biopsies and facilitating the access of the many drugs that have been proved efficacious against cancer out of the brain might offer new opportunities. Our contribution to Nanobright is intended to apply light using specific probes develop within the consortium to provide clinically relevant applications for these technologies using advanced tumor models as well as human samples.
15:30 - 16:00 Webinar: Chengjie Ding
16:00 - 16:30 Progress Report: Chengjie Ding
15:30 - 16:00 Webinar: Liam Conlard
16:00 - 16:30 Progress report: Liam Conlard